Pharmaxis seeks US FDA OK for inhaled mannitol in CF
This article was originally published in Scrip
Executive Summary
Australian specialty drug maker Pharmaxis submitted a new drug application (NDA) to the US FDA for Bronchitol, a formulation of mannitol administered as a dry powder in a hand?held inhaler, as a treatment for patients with cystic fibrosis.